CYP19A1 and metabolic dysfunction-associated steatotic liver disease: Lee et al., including 253 patients undergoing aromatase inhibitor therapy which led to the development of NAFLD, reported a lower disease-free survival than those without NAFLD (HR, 2.8 95% CI: 1.26–6.23, p = 0.012) [32] and Brown et al. including 387 people with multiple cancer types reported an association with increased risk of all-cause (HR: 2.52, 95% CI: 1.47–4.34; p = 0.001) and cancer-specific mortality (and HR: 3.21, 95% CI: 1.46–7.07; p = 0.004) with NAFLD [22].